Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice

Charlotte Sumner, Claribel D. Wee, Leigh C. Warsing, Dong W. Choe, Andrew S. Ng, Cathleen Lutz, Kathryn Rae Wagner

Research output: Contribution to journalArticle

Abstract

There is currently no treatment for the inherited motor neuron disease, spinal muscular atrophy (SMA). Severe SMA causes lower motor neuron loss, impaired myofiber development, profound muscle weakness and early mortality. Myostatin is a transforming growth factor-β family member that inhibits muscle growth. Loss or blockade of myostatin signaling increases muscle mass and improves muscle strength in mouse models of primary muscle disease and in the motor neuron disease, amyotrophic lateral sclerosis. In this study, we evaluated the effects of blocking myostatin signaling in severe SMA mice (hSMN2/delta7SMN/ mSmn-/-) by two independent strategies: (i) transgenic overexpression of the myostatin inhibitor follistatin and (ii) post-natal administration of a soluble activin receptor IIB (ActRIIB-Fc). SMA mice overexpressing follistatin showed little increase in muscle mass and no improvement in motor function or survival. SMA mice treated with ActRIIB-Fc showed minimal improvement in motor function, and no extension of survival compared with vehicle-treated mice. Together these results suggest that inhibition of myostatin may not be a promising therapeutic strategy in severe forms of SMA.

Original languageEnglish (US)
Pages (from-to)3145-3152
Number of pages8
JournalHuman Molecular Genetics
Volume18
Issue number17
DOIs
StatePublished - 2009

Fingerprint

Myostatin
Spinal Muscular Atrophy
Follistatin
Muscles
Motor Neuron Disease
Muscle Weakness
Amyotrophic Lateral Sclerosis
Muscle Strength
Transforming Growth Factors
Motor Neurons
Inhibition (Psychology)
Mortality
Growth

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. / Sumner, Charlotte; Wee, Claribel D.; Warsing, Leigh C.; Choe, Dong W.; Ng, Andrew S.; Lutz, Cathleen; Wagner, Kathryn Rae.

In: Human Molecular Genetics, Vol. 18, No. 17, 2009, p. 3145-3152.

Research output: Contribution to journalArticle

Sumner, Charlotte ; Wee, Claribel D. ; Warsing, Leigh C. ; Choe, Dong W. ; Ng, Andrew S. ; Lutz, Cathleen ; Wagner, Kathryn Rae. / Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. In: Human Molecular Genetics. 2009 ; Vol. 18, No. 17. pp. 3145-3152.
@article{6b260b1eb6bb4f0387ec009a0958cdb9,
title = "Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice",
abstract = "There is currently no treatment for the inherited motor neuron disease, spinal muscular atrophy (SMA). Severe SMA causes lower motor neuron loss, impaired myofiber development, profound muscle weakness and early mortality. Myostatin is a transforming growth factor-β family member that inhibits muscle growth. Loss or blockade of myostatin signaling increases muscle mass and improves muscle strength in mouse models of primary muscle disease and in the motor neuron disease, amyotrophic lateral sclerosis. In this study, we evaluated the effects of blocking myostatin signaling in severe SMA mice (hSMN2/delta7SMN/ mSmn-/-) by two independent strategies: (i) transgenic overexpression of the myostatin inhibitor follistatin and (ii) post-natal administration of a soluble activin receptor IIB (ActRIIB-Fc). SMA mice overexpressing follistatin showed little increase in muscle mass and no improvement in motor function or survival. SMA mice treated with ActRIIB-Fc showed minimal improvement in motor function, and no extension of survival compared with vehicle-treated mice. Together these results suggest that inhibition of myostatin may not be a promising therapeutic strategy in severe forms of SMA.",
author = "Charlotte Sumner and Wee, {Claribel D.} and Warsing, {Leigh C.} and Choe, {Dong W.} and Ng, {Andrew S.} and Cathleen Lutz and Wagner, {Kathryn Rae}",
year = "2009",
doi = "10.1093/hmg/ddp253",
language = "English (US)",
volume = "18",
pages = "3145--3152",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice

AU - Sumner, Charlotte

AU - Wee, Claribel D.

AU - Warsing, Leigh C.

AU - Choe, Dong W.

AU - Ng, Andrew S.

AU - Lutz, Cathleen

AU - Wagner, Kathryn Rae

PY - 2009

Y1 - 2009

N2 - There is currently no treatment for the inherited motor neuron disease, spinal muscular atrophy (SMA). Severe SMA causes lower motor neuron loss, impaired myofiber development, profound muscle weakness and early mortality. Myostatin is a transforming growth factor-β family member that inhibits muscle growth. Loss or blockade of myostatin signaling increases muscle mass and improves muscle strength in mouse models of primary muscle disease and in the motor neuron disease, amyotrophic lateral sclerosis. In this study, we evaluated the effects of blocking myostatin signaling in severe SMA mice (hSMN2/delta7SMN/ mSmn-/-) by two independent strategies: (i) transgenic overexpression of the myostatin inhibitor follistatin and (ii) post-natal administration of a soluble activin receptor IIB (ActRIIB-Fc). SMA mice overexpressing follistatin showed little increase in muscle mass and no improvement in motor function or survival. SMA mice treated with ActRIIB-Fc showed minimal improvement in motor function, and no extension of survival compared with vehicle-treated mice. Together these results suggest that inhibition of myostatin may not be a promising therapeutic strategy in severe forms of SMA.

AB - There is currently no treatment for the inherited motor neuron disease, spinal muscular atrophy (SMA). Severe SMA causes lower motor neuron loss, impaired myofiber development, profound muscle weakness and early mortality. Myostatin is a transforming growth factor-β family member that inhibits muscle growth. Loss or blockade of myostatin signaling increases muscle mass and improves muscle strength in mouse models of primary muscle disease and in the motor neuron disease, amyotrophic lateral sclerosis. In this study, we evaluated the effects of blocking myostatin signaling in severe SMA mice (hSMN2/delta7SMN/ mSmn-/-) by two independent strategies: (i) transgenic overexpression of the myostatin inhibitor follistatin and (ii) post-natal administration of a soluble activin receptor IIB (ActRIIB-Fc). SMA mice overexpressing follistatin showed little increase in muscle mass and no improvement in motor function or survival. SMA mice treated with ActRIIB-Fc showed minimal improvement in motor function, and no extension of survival compared with vehicle-treated mice. Together these results suggest that inhibition of myostatin may not be a promising therapeutic strategy in severe forms of SMA.

UR - http://www.scopus.com/inward/record.url?scp=68749088558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749088558&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddp253

DO - 10.1093/hmg/ddp253

M3 - Article

C2 - 19477958

AN - SCOPUS:68749088558

VL - 18

SP - 3145

EP - 3152

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 17

ER -